Introduction
Physical exercise and the inhalation of cold, dry air can provoke acute bronchoconstriction in susceptible individuals.
Competitive cross-country skiers perform sustained, strenuous exercise during which they inhale large volumes of cold air, often at temperatures below -15°C. Obstructive airway symptoms and asthma are 2-6 times more common among competitive cross-country skiers in Norway (1) and Sweden (2,3) than in the normal population.
However, due to differences in methodology, it is not possible to directly compare the findings in these studies. Furthermore, a persistent increase in bronchial responsiveness has been reported in elite Swedish skiers. It has been proposed that strenuous training at low temperatures with the repeated Received 4 June 1995 and accepted 14 June 1995. iAuthor to whom correspondence should be addressed at: Department of Lung Medicine, University Hospital, N-7006 Trondheim, Norway.
0954-611 l/96/020099+07 $12.0010 inhalation of large amounts of cold air may be asthmagenic (2).
In central Scandinavia, the neighbouring counties of Trondelag in Norway and Jamtland in Sweden have different winter climates. The former, because of its coastal location, has milder winters than the latter, which has an inland climate with colder, drier air in the winter. This study was designed in order to compare the prevalence of asthma symptoms, bronchial hyper-responsiveness (BHR) and asthma in young, competitive cross-country skiers from the two regions. (TABLE 1) The study population consisted of 171 young, elite cross-country skiers, who were attending senior secondary schools in Norway (118 skiers) and Sweden (38 skiers), or serving as conscripted soldiers in a Swedish military ski-platoon (15 skiers). There were All subjects, as well as the parents of those subjects under 18 years of age, gave written informed consent, and the study was approved by the Regional Ethics Committee in Trondheim.
Materials and Methods

STUDY POPULATION
QUESTIONNAIRE
All subjects completed a questionnaire in their native language. Each skier was asked to estimate the time spent in training during the previous year and the number of years of competition.
The questionnaire also included questions about known respiratory allergy, cigarette smoking, medical consultations within the last 5 yr for respiratory symptoms, and physician diagnosis of asthma. Each skier was asked about the use of anti-asthmatic medication and the presence within the last year of respiratory symptoms, such as cough, attacks of shortness of breath, chest tightness and wheezing. It was also determined whether these symptoms were present on exercise, or on exposure to cold conditions and irritants.
LUNG FUNCTION
Lung function (FEV,, FVC, and percentage of their predicted values) in each subject was assessed by spirometry using a Microlab 3300 Mk2 spirometer (Micro Medical Ltd). The better of two measurements with less than 5% variation was recorded.
BRONCHIAL
HYPER-RESPONSIVENESS (BHR)
The bronchial responsiveness of each subject to methacholine was assessed by a controlled tidal volume breathing technique (4). The Spira Elektro 2 automatic inhalation synchronized dosimeter jet nebulizer (Respiratory Care Centre, Hameenlinna, Finland) was used. The nebulization time was 0.5 s, starting after the inhalation of 100 ml of the tidal volume. For each inhalation, the inspiratory flow rate did not exceed 0.5 1 s ~ ' and the inspired volume was at least 0.5 1. The mean (SD) output of the nebulizer, determined by five weighings on a gravimetric balance, was 5.0 (0.5) ,~l inhalation -'.
Bronchodilators were withheld on the day of investigation.
Each skier practised with the dosimeter before the start of the test. Baseline spirometry after the inhalation of 0.9% saline was performed initially.
Methacholine concentrations of 2.5 mg ml -i and 25 mg ml-' were used. A cumulative dose of 1800,~g (9.1 pmol) methacholine was administered in four stages-four and 11 inhalations of methacholine 2.5 mg ml -', followed by three and 10 inhalations of methacholine 25 mg ml -'. FEV, was measured 90 s after the completion of each of the first three stages and 180 s after the final stage. The better of two measurements with less than 5% variation was recorded. The test was stopped if the FEV, fell by 20% or more, relative to baseline FEV,. Subjects with a PD,, FEV, of I 1800 pg (9.1 pmol) methacholine were considered to have BHR. In both groups, the predominant symptoms were wheeze and exercise-related chest tightness within the last year, and abnormal shortness of breath on exercise and with exposure to airway irritants. Wheeze was reported by at least 45% of skiers. Every third skier in each group complained of chest tightness on exertion within the last year, and breathlessness on exposure to airway irritants. Abnormal shortness of breath on exertion was reported by at least every fourth skier in each group. Wheeze together with attacks of shortness of breath was reported by 35% of skiers in both groups.
Cough on winter training was reported significantly more often by skiers in Sweden than in Norway (64% and 42% respectively, PcO.01). Cough under other circumstances was infrequent. Exacerbation of symptoms on exposure to cold was three times more frequent among Swedish skiers (45% vs. 14%, P<O.OOl).
ASTHMA SYMPTOMATOLOGY
Positive asthma symptomatology was present in almost every other skier in both groups (Fig. 1) . (Table 3) with cough on winter training in both groups (Norway, P<O.OOl, Sweden, P<O.Ol), and exacerbation of symptoms on exposure to cold conditions in Sweden alone (P<O.OOl).
It was associated
BRONCHIAL
HYPER-RESPONSIVENESS Bronchial hyper-responsiveness was three times more prevalent in Sweden than in Norway (43% vs. 14%, P<O.OOl) (Fig. 1) . It was not associated with cough on winter training, or with exacerbation of symptoms on exposure to cold conditions in either group (Table 3) . One-third of the hyper-responsive skiers were asymptomatic, with no differences between the countries.
CURRENT ASTHMA
The prevalence of current asthma, defined as BHR with asthma symptomatology, was three times greater in Sweden (28% vs. 9%, PcO.01) (Fig. 1) . Current asthma was associated with winter cough (PcO.01) and with exacerbation of symptoms on exposure to cold conditions (P~0.01) in Swedish skiers alone (Table 3) . 
Physician consultation
rate was significantly greater among Swedish skiers than Norwegian skiers (40% vs. 24%, PcO.05). Swedish skiers with asthma symptoms were more likely to consult their physician. Of those skiers with positive asthma symptomatology, 59% from Sweden (16 skiers) and 35% from Norway (19 skiers) had consulted their doctor within the preceding 5 yr (PcO.05).
ASTHMA DIAGNOSIS
A physician diagnosis of asthma was reported by 26% and 10% of skiers from Sweden and Norway, respectively (PcO.01).
Of 14 Norwegian skiers fulfilling the criteria for current asthma, six skiers had not consulted their doctor and an additional three skiers were not diagnosed by their doctor. Of 22 Swedish skiers with asthma, seven skiers had not consulted their doctor and an additional four skiers were not diagnosed by their doctor.
ANTI-ASTHMATIC MEDICATION
The use of anti-asthmatic medication within the last year was reported by 38% and 16% of Swedish and Norwegian skiers, respectively (P<O.Ol).
The most commonly used drugs in both groups were the &agonists, used by 38% and 14% of Swedish and Norwegian skiers, respectively (P~O.001). Inhaled corticosteroids were used by 23% of Swedish skiers and by 4% of Norwegian skiers (P<O.OOl). Sodium cromoglycate was used by 4% of skiers.
Bronchodilators were used for symptomatic treatment. Of 50 (29 Norwegian and 21 Swedish) skiers who had consulted their doctor, 34 (15 Norwegian and 19 Swedish) used bronchodilator therapy. All except three of these skiers (one from Sweden and two from Norway) had positive asthma symptomatology. All skiers with current asthma who had consulted their doctors were on bronchodilator therapy.
TOTAL ASTHMA
The prevalence of total asthma, defined as physician-diagnosed asthma currently treated with corticosteroids (10 skiers) in addition to current asthma, was 3.5 times greater in Sweden than in Norway (42% vs. 12%, P<O.OOl) (Fig. 1) .
SELF-REPORTED RESPIRATORY ALLERGY
The prevalence of self-reported allergy was three times greater in Sweden than in Norway (32% vs. ll%, PO.001) (Fig. 1) . However, in both groups, self-reported respiratory allergy was independent of asthma symptomatology, BHR and current asthma (Table 4 ).
Discussion
In this study of young, elite cross-country skiers in central Scandinavia, the prevalence of asthma symptomatology was similar in both countries. However, the prevalence of BHR and asthma was three times greater in Swedish than in Norwegian skiers.
It is most unlikely that the differences in prevalence of asthma and BHR could be due to methodological errors. The protocol and equipment for spirometry and measurement of BHR were the same in both locations. Furthermore, the instruments were compared to each other and found to be identical regarding volume measurement (spirometry) and methacholine output (Spira Elektro 2 nebulizer).
The prevalence of asthma symptomatology in these Swedish skiers is twice that found in an earlier study of Swedish cross-country skiers (3). The definition of asthma symptomatology in these two studies was identical. However, the study populations were different. The study population in the present study were skiers from Central Sweden only, while the previous study included skiers from all the ski schools in Sweden as well as members of the training groups of the national team.
Asthma symptoms have been reported to occur more frequently among cross-country skiers than in the general population exposed to similar conditions (3). In Northern Sweden where the winter climate is cold, the prevalence of asthma symptoms among lCyear-olds has been reported to be one-half of that found in the present study (5). The frequency of wheezing with attacks of breathlessness was five times greater in this study than in a recently reported study of the general population from this region (6). The reasons for the high prevalence of BHR among the Swedish skiers are unknown.
It is not thought that BHR to methacholine was overestimated in the present study as a cut-off point of 9.1 pmol was used, which is lower than the 13.2 pmol chosen by Nieminen et al. (4). Arbitrary cut-off points of 6.4 pmol and 7.8 pmol have been chosen in other studies (7, 8) in which, however, other nebulizers were used. Prior to the present study, a comparison was made between the present study method and the previously used standardized method as described by Juniper et al. (9) . A good agreement was found with the maximum PD,, dose of 9.1 pmol not exceeding a dose corresponding to PC,, ~8 mg ml -' methacholine with the Juniper method (data not shown).
Although the prevalence of self-reported respiratory allergy was three times higher in Sweden, there was no association between BHR and self-reported allergy in either group. As atopic individuals have been reported to be significantly more responsive to methacholine than non-atopic individuals (lo), this was unexpected.
One possible explanation is the differences in the winter climatic conditions between the two regions. Inhalation of cold, dry air for 10 min by healthy individuals results in a transient increase in bronchial responsiveness to histamine (11). The volume ventilated in 1 min by cross-country skiers can be increased 40-fold during hard training and competition compared to ventilation at rest. It is thus possible that the hyperpnoea and exposure to cold air may have a cumulative effect on bronchial responsiveness. The Swedish skiers reported a significantly higher frequency of exacerbation of respiratory symptoms on exposure to cold weather. This was not unexpected as the degree of exposure to cold air was significantly greater in the Swedish skiers, in terms of exposure to a colder climate as well as years of skiing experience.
It is unknown whether the BHR in this crosssectional study of skiers was persistent as found previously (2).
The present definition of current asthma required the presence of wheeze and breathlessness or chest tightness together with BHR. Wheeze within the previous year and BHR has been proposed as a 'gold standard' for current asthma in epidemiological studies (12) . The prevalence of current asthma using this definition would be 9% and 25% in the Norwegian and Swedish skiers, respectively, which is very close to that found using the present definition.
The higher prevalence of current asthma among the Swedish skiers was due to differences in bronchial responsiveness. The prevalence approached that of 33% reported in a study of more experienced and older Swedish cross-country skiers (2). In a study of high-level Norwegian skiers, the prevalence of selfreported asthma was 14%, three times greater than that of non-skiing controls (1).
The prevalence of current asthma in teenagers in Northern Sweden was one-quarter (5) and in 16-yearolds in the county of Jamtland was one-third (13) of that found in the present group of Swedish skiers. In both studies, the definition of current asthma was close to the present definition. Thus the prevalence of current asthma in cross-country skiers is greater than in the general population exposed to similar climatic conditions. Anti-asthmatic medication was used mainly for symptomatic treatment, especially among Swedish skiers. The medication rate was similar to that in elite, adult Swedish skiers (2). As a complement to medication, non-pharmacological management of this type of asthma should be emphasized. Such measures include a more liberal use of heat and moisture-retaining masks, and avoidance of training and competition under extremely low ambient temperature conditions.
In conclusion, there is a high prevalence of BHR and asthma among young, elite cross-country skiers in central Scandinavia, especially in Sweden. Competitive cross-country skiing may be a risk factor for the development of asthma. Longitudinal studies of cross-country skiers, and studies to acquire further knowledge of the mechanisms involved in the development of asthma are indicated, as are studies exploring the pathophysiology of this type of asthma.
